Development of mini-SSPedi for children 4–7 years of age receiving cancer treatments

Tomlinson, Deborah; Hyslop, Shannon; Stein, Eliana; Spiegler, Brenda J.; Vettese, Emily; Kuczynski, Susan; Schechter, Tal; Dupuis, L. Lee; Sung, Lillian

doi:10.1186/s12885-018-5210-z

Cited by 29 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although pediatric oncology clinicians have a broad awareness of children’s symptoms, routine symptom assessment is often guided by regulatory criteria such as Joint Commission expectations for pain assessment (Linder & Wawrzynski, 2018). Resources to support children’s self-report of symptoms in the clinical setting are emerging and are being developed for children as young as 4 years of age (Dupuis et al, 2018; Tomlinson et al, 2014; Tomlinson et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Linder

Hooke

2019

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

Children and adolescents receiving treatment for cancer experience multiple symptoms as a consequence of their disease and its treatment that interfere with the child’s quality of life. Understanding of symptom assessment in children with cancer is foundational to the work of the Children’s Oncology Group Nursing Discipline, whose research aims are to address knowledge gaps including understanding illness-related distress. This article is the second of a two-part summary of current evidence addressing the assessment of symptoms frequently reported by children and adolescents receiving treatment for cancer. Studies reporting assessment of pain, sadness, and symptom clusters published between January 2008 and May 2018 were included. Forty-three publications addressed pain. Pain was highly prevalent and distressing, varied in its trajectory across a cycle of chemotherapy and across multiple cycles of treatment, and correlated with biomarkers associated with the pain response. Consequences of pain were poorer functional status and emotional health. Twenty publications addressed sadness. Sadness was the most prevalent psychosocial symptom. Its prevalence decreased over the course of treatment and over a cycle of chemotherapy. Persistent sadness was of greater severity and distress. Eight publications addressed symptom clusters. These studies identified both groups of co-occurring symptoms and groups of patients with common symptom profiles. This two-article series provides evidence for the distressing nature of symptoms among children receiving cancer treatment. Efforts to support clinicians in routine symptom assessment are needed. Additional research directed at alleviating symptoms and building resilience among the child experiencing symptoms is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Linder

Hooke

2019

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

show abstract

“…Of the articles included, 45 reported on response format , seven on recall period [61][62][63][64][65][66][67], 24 on administration mode , four on both recall and response format [92][93][94][95] and one on response format and administration mode [96]. The PRISMA flowchart is shown in Fig.…”

Section: Study Selectionmentioning

confidence: 99%

“…50 papers investigated ability to use specific response formats [92][93][94][95][96] (see Table 2 for details). The majority reported on one or more of the following pictorial scales, (faces pain scale revised (FPS-R) or Wong-Baker faces) (n = 24), visual analogue scales (VAS) (n = 15), and Likert scales (numerical or word descriptor) (n = 14).…”

Section: Response Formatmentioning

confidence: 99%

Enhancing validity, reliability and participation in self-reported health outcome measurement for children and young people: a systematic review of recall period, response scale format, and administration modality

et al. 2021

View full text Add to dashboard Cite

Introduction Self-report is the gold standard for measuring children’s health-related outcomes. Design of such measures is complex and challenging. This review aims to systematically appraise the evidence on recall period, response scale format, mode of administration and approaches needed to enable children and young people < 19 years to participate in valid and reliable self-reporting of their health outcomes. Method PsycInfo, Medline, CINAHL and Embase were searched from 1 January 1990 to 15 March 2020, and citation searching undertaken in Scopus. Articles were included if they were primary research or case reports of ≥ 3 participants reporting the following: recall period, response scale selection, administration modality. Quality was assessed using QualSyst, and results synthesised narratively. This review was conducted and reported according to PRISMA guidelines. Results 81 of 13,215 retrieved articles met the inclusion criteria. Children < 5 years old cannot validly and reliably self-report health outcomes. Face scales demonstrate better psychometric properties than visual analogue or Likert scales. Computerised and paper scales generally show equivalent construct validity. Children prefer computerised measures. Children ≤ 7 years old think dichotomously so need two response options. Those > 8 years old can reliably use a 3-point scale. Conclusion The results of this review have both clinical and research implications. They can be used to inform appropriate choice of PROM for use with CYP in the clinical setting. We also give eight recommendations for future development of self-reported outcome measures for children and young people.

show abstract

“…10 Similarly, translation of a symptom screening tool for younger children is also important. While such a tool has been developed for children 4-7 years of age, 11 it has not yet been validated in English.…”

Section: Discussionmentioning

confidence: 99%

Translating the Symptom Screening in Pediatrics Tool (SSPedi) into French and among French-speaking children receiving cancer treatments, evaluating understandability and cultural relevance in a multiple-phase descriptive study

et al. 2020

Self Cite

View full text Add to dashboard Cite

ObjectivesSymptom Screening in Pediatrics Tool (SSPedi) is a validated approach to measuring bothersome symptoms for English-speaking and Spanish-speaking children with cancer and paediatric haematopoietic stem cell transplantation (HSCT) recipients. Objectives were to translate SSPedi into French, and among French-speaking children receiving cancer treatments, to evaluate understandability and cultural relevance.MethodsWe conducted a multiphase, descriptive study to translate SSPedi into French. Forward translation was performed by four medical translators. After confirming that back translation was satisfactory, we enrolled French-speaking children with cancer and paediatric HSCT recipients at four centres in France and Canada.Primary and secondary outcome measuresUnderstandability was evaluated by children themselves who self-reported degree of difficulty, and by two adjudicators who rated incorrectness. Assessment of cultural relevance was qualitative. Participants were enrolled in cohorts of 10.ResultsThere were 30 children enrolled. Participants were enrolled from Marseille (n=10, 33%), Ottawa (n=1, 3%), Quebec City (n=11, 37%) and Toronto (n=8, 27%). No child reported that it was hard or very hard to complete French SSPedi in the last cohort of 10 participants. Changes to the instrument itself were not required. After enrolment of 30 respondents, the French translation of SSPedi was considered finalised based on self-reported difficulty with understanding, adjudicated incorrect understanding and cultural relevance.ConclusionsWe translated and finalised SSPedi for use by French-speaking children and adolescents receiving cancer treatments. Future work should begin to use the translated version to conduct research and to facilitate clinical care.

show abstract

Development of mini-SSPedi for children 4–7 years of age receiving cancer treatments

Cited by 29 publications

References 15 publications

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Enhancing validity, reliability and participation in self-reported health outcome measurement for children and young people: a systematic review of recall period, response scale format, and administration modality

Translating the Symptom Screening in Pediatrics Tool (SSPedi) into French and among French-speaking children receiving cancer treatments, evaluating understandability and cultural relevance in a multiple-phase descriptive study

Contact Info

Product

Resources

About